Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Sep;20(9):959-964.
doi: 10.1080/14712598.2020.1789097. Epub 2020 Jul 2.

COVID-19 pneumonia and immune-related pneumonitis: critical issues on differential diagnosis, potential interactions, and management

Marco Russano  1 , Fabrizio Citarella  1 , Andrea Napolitano  1 , Emanuela Dell'Aquila  1 , Alessio Cortellini  2   3 , Francesco Pantano  1 , Bruno Vincenzi  1 , Giuseppe Tonini  1 , Daniele Santini  1
Affiliations
Editorial

COVID-19 pneumonia and immune-related pneumonitis: critical issues on differential diagnosis, potential interactions, and management

Marco Russano et al. Expert Opin Biol Ther. 2020 Sep.

Abstract

Introduction: The COVID-19 pandemic occurred amid the cancer immunotherapy revolution. Immune checkpoint inhibitors (ICIs) have become the standard of care for several solid cancers and are associated with peculiar toxicities, including pneumonitis which has similar features to COVID-19 pneumonia.

Areas covered: We summarize the main hallmarks of lung injury induced by ICIs and severe acute respiratory syndrome coronavirus 2 and discuss the critical aspects for differential diagnosis and management. Symptoms and radiological findings are often similar; conversely, treatments are quite different. Furthermore, we focus on potential interactions generating hypotheses that need confirmatory studies.

Expert opinion: All cancer patients treated with immunotherapy should receive screening for SARS-CoV-2. This would improve the diagnosis and management of pneumonia and guide therapeutic choices. Furthermore, clinicians could estimate the risk/benefit of continuing ICI treatment in COVID-19 positive patients. Temporary withdrawal of the immunotherapy treatment pending resolution of viral infection may be a reasonable option in long-responders patients.

Keywords: COVID-19; coronavirus; immune checkpoint inhibitors; immune-related Pneumonitis; immunotherapy; pneumonia.

PubMed Disclaimer

Similar articles

  • Potential protective and therapeutic role of immune checkpoint inhibitors against viral infections and COVID-19.
    Gatto L, Franceschi E, Nunno VD, Brandes AA. Gatto L, et al. Immunotherapy. 2020 Oct;12(15):1111-1114. doi: 10.2217/imt-2020-0109. Epub 2020 Jun 29. Immunotherapy. 2020. PMID: 32594820 Free PMC article. No abstract available.
  • Pneumonitis from immune checkpoint inhibitors and COVID-19: current concern in cancer treatment.
    Rossi E, Schinzari G, Tortora G. Rossi E, et al. J Immunother Cancer. 2020 Jul;8(2):e000952. doi: 10.1136/jitc-2020-000952. J Immunother Cancer. 2020. PMID: 32699182 Free PMC article.
  • Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists.
    Ottaviano M, Curvietto M, Rescigno P, Tortora M, Palmieri G, Giannarelli D, Aieta M, Assalone P, Attademo L, Avallone A, Bloise F, Bosso D, Borzillo V, Buono G, Calderoni G, Caputo F, Cartenì G, Cavallero D, Cavo A, Ciardiello F, Conca R, Conteduca V, De Falco S, De Felice M, De Laurentiis M, De Placido P, De Placido S, De Santo I, De Stefano A, Della Corte CM, Di Franco R, Di Lauro V, Fabbrocini A, Federico P, Festino L, Giordano P, Giuliano M, Gridelli C, Grimaldi AM, Lia M, Marretta AL, Massa V, Mennitto A, Merler S, Merz V, Messina C, Messina M, Milano M, Minisini AM, Montesarchio V, Morabito A, Morgillo F, Mucci B, Nappi L, Napolitano F, Paciolla I, Pagliuca M, Palmieri G, Parola S, Pepe S, Petrillo A, Piantedosi F, Piccin L, Picozzi F, Pietroluongo E, Pignata S, Prati V, Riccio V, Rosanova M, Rossi A, Russo A, Salati M, Santabarbara G, Sbrana A, Simeone E, Silvestri A, Spada M, Tarantino P, Taveggia P, Tomei F, Vincenzo T, Trapani D, Trojanello C, Vanella V, Vari S, Ventriglia J, Vitale MG, Vitiello F, Vivaldi C, von Arx C, Zacchi F, Zampiva I, Zivi A, Daniele B, Ascierto PA; SCITO (Società Campana di ImmunoTerapia Oncologica). Ottaviano M, et al. J Immunother Cancer. 2020 Oct;8(2):e001154. doi: 10.1136/jitc-2020-001154. J Immunother Cancer. 2020. PMID: 33060148 Free PMC article.
  • COVID-19 and management of neuroimmunological disorders.
    Hartung HP, Aktas O. Hartung HP, et al. Nat Rev Neurol. 2020 Jul;16(7):347-348. doi: 10.1038/s41582-020-0368-9. Nat Rev Neurol. 2020. PMID: 32444648 Free PMC article. Review.
  • Facing SARS-CoV-2 outbreak in immunotherapy era.
    Citarella F, Russano M, Pantano F, Dell'Aquila E, Vincenzi B, Tonini G, Santini D. Citarella F, et al. Future Oncol. 2020 Jul;16(20):1475-1485. doi: 10.2217/fon-2020-0340. Epub 2020 May 29. Future Oncol. 2020. PMID: 32468851 Free PMC article. Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020. February 14;21(3):335–337. published online. - PMC - PubMed
    1. Yu J, Ouyang W, Chua MLK, et al. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China. [published online ahead of print, 2020 Mar 25]. JAMA Oncol. 2020;e200980. DOI:10.1001/jamaoncol.2020.0980 - DOI - PMC - PubMed
    1. Xia Y, Jin R, Zhao J, et al. Risk of COVID-19 for cancer patients. Lancet Oncol. 2020. March 3; ii: S1470-2045(20)30150–9. DOI:10.1016/S1470-2045(20)30150-9. - DOI - PMC - PubMed
    1. Wang J, Luo Q, Chen R, et al. Susceptibility analysis of COVID-19 in smokers based on ACE2. Preprints. 2020;2020030078. DOI:10.20944/preprints202003.0078.v1. - DOI
    1. Kroschinsky F, Stölzel F, von Bonin S, et al. New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. Crit Care. 2017. April 14;21(1):89. - PMC - PubMed

Publication types